Medical researchers who are interested in initiating a thalassemia-related project or who have an existing project that requires additional funding: The Cooley’s Anemia Foundation may be just what you need.
CAF has a decades-long history of supporting innovative and important research in thalassemia. Our established and respected Medical Fellowship program has funded numerous early career individuals who have continued to stay in the thalassemia field and make important contributions to the scientific and clinical study of thalassemia.
Our Support for Ongoing Clinical Research in Thalassemia Grants and Clinical Trials in Thalassemia Cell and Gene Therapy Grants are aggressively pushing forward the understanding of issues of concern to the growing thalassemia population and helping to propel advances in areas of primary importance.
October 28, 2015 – A packed house of 240 clinicians, scientists, nurses, industry, consumers and other participants attended the 10th Cooley’s Anemia Symposium in Rosemont, IL from October 18-22. This invaluable meeting, presented by the Cooley’s Anemia Foundation (CAF) and the New York Academy of Sciences(NYAS) is an anticipated and milestone event held only every […]
July 29, 2015 – Three new Cooley’s Anemia Foundation Medical Research Fellowships have been awarded for the 2015-2016 grant cycle. Combined with the three Fellowships which have been renewed from the previous cycle, the total amount of research funding for the current cycle comes to $195,000. The recipients were selected by members of the CAF […]
February 2, 2015 – Thalassaemia International Federation ( TIF) has announced a new thalassemia fellowship opportunity, established in honor of the late Renzo Galanello, Professor of Pediatrics at the University of Cagliari, Italy, and Director of the 2nd Pediatric Clinic, Department of Biomedical Sciences and Biotechnologies, Ospedale Regionale per le Microcitemie. Dr. Galanello was a respected and […]
December 11, 2014 – Exciting data from studies looking at new treatments for thalassemia presented at the annual meeting of the American Society of Hematology builds upon science supported by the Cooley’s Anemia Foundation and gives hope for the development of significant new treatments for the genetic blood disorder known as thalassemia. Two of the […]
August 25, 2014 – New explorations in gene editing. Connections between thyroid hormones and hemoglobin. Efficiency and safety in gene therapy. Using a protein to control iron. These are the ideas behind the four exciting new studies being funded by the Cooley’s Anemia Foundation this year. These new fellowships join four renewed fellowships and a […]
bluebird bio, a Cambridge, MA- based biotechnology company, is sponsoring the Northstar Study, investigating gene transfer as a curative option for beta-thalassemia. More information about the study, including eligibility requirements, can be found at http:///www.northstarstudy.com. The Northstar Study is now enrolling adults who are transfusion dependent and diagnosed with a beta thalassemia major. The goal […]
December 2, 2013 – bluebird bio, Inc. today announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 HGB-205 study in France and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation. “We believe gene therapy represents a potentially new and exciting treatment […]
October 21, 2013 – The Cooley’s Anemia Foundation is accepting applications for medical research grants and fellowships in areas related to thalassemia. Details are as follows: SUPPORT FOR ONGOING CLINICAL RESEARCH IN THALASSEMIA The Cooley’s Anemia Foundation invites national and international applications for 2014-2015 grants to support ongoing clinical research projects in Thalassemia. The goal […]
July 15, 2013 – What would motivate a person with thalassemia to make changes to improve adherence to therapy? Can metabolic substances in a person with thalassemia give a clue to how iron is loading in his/her heart? Would moving the fetal hemoglobin gene cause it to create more fetal hemoglobin? These are just some […]
June 20, 2013 – The American Heart Association (AHA) has released a consensus statement on “Cardiovascular Function and Treatment in Beta-Thalassemia Major.” Published online in the AHA journal Circulation, the document states in part that “central to early identification of cardiac iron overload in TM (thalassemia major) is the estimation of cardiac iron by cardiac […]
